Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus S-1 for advanced esophageal squamous cell carcinoma
ChiCTR-OIH-17012822Phase 2Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Sep 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and tegafur in Esophageal Squamous Cell Carcinoma (ESCC) and esophageal cancer, sponsored by Shanxi Cancer Hospital. Primary endpoints: Progression-free survival and Safety. Started Sep 2017; status: recruiting.
02
Drugs
Rivoceranibtegafur
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal cancer
Beyond the preview
Go deeper on ChiCTR-OIH-17012822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIH-17012822.